Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates
Journal of Thrombosis and Haemostasis · 2026-11 · 24 (11) · 3865-3873
DOI: 10.1016/j.jtha.2026.08.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-11. Verfasst von Davide Matino und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University and the Thrombosis and Atherosclerosis Research Institute (TaARI), Hamilton, Ontario, Canada; Hamilton He…. Hauptthemen laut MEDLINE: Hemophilia B, Factor IX, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, McMaster University and the Thrombosis and Atherosclerosis Research Institute (TaARI), Hamilton, Ontario, Canada; Hamilton Health Sciences Hemophilia Clinic, Hamilton, Ontario, Canada. Electronic…
- Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.
- Division of Hematology, Children's Hospital of Philadelphia; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Division of Hematology, Department of Pediatrics, Children's H…
- School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.
- Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy.
- Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Zitieren
APA
Matino, D., Al-Housni, Z., Samelson-Jones, B., Chelle, P., Castaman, G., Teitel, J., Jackson, S., Lillicrap, D., Keepanasseril, A., Chan, A., Lee, K., Edginton, A., & Iorio, A. (2026). Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates. Journal of Thrombosis and Haemostasis, 24(11), 3865-3873. https://doi.org/10.1016/j.jtha.2026.08.010
Vancouver
Matino D, Al-Housni Z, Samelson-Jones B, Chelle P, Castaman G, Teitel J, et al. Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates. Journal of Thrombosis and Haemostasis. 2026;24(11):3865-3873. doi:10.1016/j.jtha.2026.08.010
BibTeX
@article{Matino2026,
author = {Matino, Davide and Al-Housni, Zainab and Samelson-Jones, Benjamin and Chelle, Pierre and Castaman, Giancarlo and Teitel, Jerome and Jackson, Shannon and Lillicrap, David and Keepanasseril, Arun and Chan, Anthony and Lee, Kyumin and Edginton, Andrea and Iorio, Alfonso},
title = {Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {11},
pages = {3865--3873},
doi = {10.1016/j.jtha.2026.08.010}
}
EUVIMED